Skip to content

Albireo up ahead of late-stage odevixibat data readout

September 8, 2020

Thinly traded micro cap Albireo Pharma (NASDAQ:ALBO) perks up 10% premarket on light volume ahead of this morning’s conference call (8:30 am ET) to discuss topline results from a Phase 3 clinical trial, PEDFIC 1, evaluating lead candidate odevixibat in patients with a rare inherited disorder called progressive familial intrahepatic cholestasis (PFIC) in which liver cells are unable to secrete bile due to mutations in a gene the encodes a protein that plays a key role in bile acid homeostasis (stable equilibrium).

The company announced Phase 2 results in June 2019 that showed treatment with odevixibat reduced serum bile acid levels as much as 92%.

Odevixibat selectively inhibits a protein called the ileal bile acid transporter (IBAT), which, as the name implies, plays a key role in transporting bile from the liver to the colon.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: